Plain-English translation of NCT05003388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing cultured allogeneic adult umbilical cord derived mesenchymal stem cells given as a single intravenous infusion to treat multiple sclerosis. Researchers will give you 100 million of these cells through an IV and then monitor you closely over four years to see if the treatment is safe and whether it helps your MS symptoms. For people with more severe disease, an additional personalized T cell vaccine made from your own immune cells may also be used.
Multiple sclerosis can be a serious and disabling condition, and current treatments don't work for everyone. Early research suggests that stem cell therapy may be safe and helpful for MS, so this trial is testing whether this approach could offer a new treatment option.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of stem cells in the treatment center. After that, you'll have follow-up visits at one month before treatment and then at 1, 6, 12, 24, 36, and 48 months after your infusion to check your safety and see how you're responding. Each visit will include medical evaluations to track any changes in your MS symptoms and watch for any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Antigua and Barbuda
Greece